Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Finished Drugs	1.02B	1.02B	1.14B	1.01B	824.06M
Finished Drugs Growth	-0.34%	-10.16%	12.49%	22.69%	15.45%
Intermediates and Bulk Medicines	151.36M	210.05M	205.09M	215.56M	255.01M
Intermediates and Bulk Medicines Growth	-27.94%	2.42%	-4.86%	-15.47%	-7.23%
Elimination of Intersegment Sales	-109.32M	-80.63M	-64.64M	-61.42M	-54.80M
Total	1.06B	1.15B	1.28B	1.17B	1.02B
Total Growth	-7.89%	-9.90%	9.66%	13.75%	7.82%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Mainland China	1.05B	1.13B	1.22B	1.10B	929.09M
Mainland China Growth	-7.53%	-6.92%	10.51%	18.70%	8.12%
Other Countries	11.29M	16.73M	58.94M	62.35M	95.18M
Other Countries Growth	-32.52%	-71.62%	-5.46%	-34.49%	4.93%
Total	1.06B	1.15B	1.28B	1.17B	1.02B
Total Growth	-7.89%	-9.90%	9.66%	13.75%	7.82%

Source: S&P Global Market Intelligence.